News

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...
Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
The telehealth company stated that its entry to Canada will come as generic Semaglutide hits the market for the first time.
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Delivering Eye-Popping Gains. Hims & Hers rebounded by 11.76 ...
Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?